GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (FRA:12V) » Definitions » Short-Term Debt

Veracyte (FRA:12V) Short-Term Debt : €0.0 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Veracyte Short-Term Debt?

Veracyte's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.0 Mil.

Veracyte's annual Short-Term Debt declined from Dec. 2021 (€1.0 Mil) to Dec. 2022 (€0.0 Mil) but then stayed the same from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€0.0 Mil).


Veracyte Short-Term Debt Historical Data

The historical data trend for Veracyte's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Short-Term Debt Chart

Veracyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.00 - -

Veracyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Veracyte Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Veracyte Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Veracyte's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Veracyte (FRA:12V) Business Description

Traded in Other Exchanges
Address
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.

Veracyte (FRA:12V) Headlines

No Headlines